Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Millan

Showing results (21-30 of 188) with videos related to

Pageof 19
Sort By:
Current Opinion in Pharmacology|November 10, 2009
Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significanceRoberto Maggio, Mark J Millan
Therapie|August 23, 2008
Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138Mark J Millan, Mauricette Brocco
European Journal of Pharmacology|March 7, 2003
The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized ratsFrançoise Lejeune, Mark J Millan
Pharmacology, Biochemistry, and Behavior|July 16, 2011
Positive allosteric modulators at GABAB receptors exert intrinsic actions and enhance the influence of baclofen on light-induced phase shifts of hamster circadian activity rhythmsRobert L Gannon, Mark J Millan
Drug Discovery Today|July 5, 2005
Dopamine D3 receptor antagonists as therapeutic agentsJeffrey N Joyce, Mark J Millan
Brain Research|March 23, 2006
The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythmsRobert L Gannon, Mark J Millan
Neuroscience and Biobehavioral Reviews|October 5, 2013
Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiativeMark J Millan, Karen L Bales
Current Opinion in Pharmacology|December 19, 2006
Dopamine D3 receptor agonists for protection and repair in Parkinson's diseaseJeffrey N Joyce, Mark J Millan
Neuropharmacology|September 14, 2010
Positive and negative modulation of circadian activity rhythms by mGluR5 and mGluR2/3 metabotropic glutamate receptorsRobert L Gannon, Mark J Millan
Psychopharmacology|May 22, 2012
LY2033298, a positive allosteric modulator at muscarinic M₄ receptors, enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythmsRobert L Gannon, Mark J Millan
Pageof 19

Showing results (21-30 of 188) with videos related to

Sort By:
Pageof 19
Current Opinion in Pharmacology|November 10, 2009
Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significanceRoberto Maggio, Mark J Millan
Therapie|August 23, 2008
Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138Mark J Millan, Mauricette Brocco
European Journal of Pharmacology|March 7, 2003
The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized ratsFrançoise Lejeune, Mark J Millan
Pharmacology, Biochemistry, and Behavior|July 16, 2011
Positive allosteric modulators at GABAB receptors exert intrinsic actions and enhance the influence of baclofen on light-induced phase shifts of hamster circadian activity rhythmsRobert L Gannon, Mark J Millan
Drug Discovery Today|July 5, 2005
Dopamine D3 receptor antagonists as therapeutic agentsJeffrey N Joyce, Mark J Millan
Brain Research|March 23, 2006
The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythmsRobert L Gannon, Mark J Millan
Neuroscience and Biobehavioral Reviews|October 5, 2013
Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiativeMark J Millan, Karen L Bales
Current Opinion in Pharmacology|December 19, 2006
Dopamine D3 receptor agonists for protection and repair in Parkinson's diseaseJeffrey N Joyce, Mark J Millan
Neuropharmacology|September 14, 2010
Positive and negative modulation of circadian activity rhythms by mGluR5 and mGluR2/3 metabotropic glutamate receptorsRobert L Gannon, Mark J Millan
Psychopharmacology|May 22, 2012
LY2033298, a positive allosteric modulator at muscarinic M₄ receptors, enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythmsRobert L Gannon, Mark J Millan
Pageof 19